TTFD/Allithiamine: The Fat-Soluble Thiamine That Gets Into the Brain

← Back to articles

Thiamine (vitamin B1) is water-soluble and uses two specific transporters — THTR1 and THTR2 — to enter cells. Above about 5 mg in a single dose, those transporters saturate and most extra thiamine is excreted in urine. Two lipid-modified versions of thiamine, TTFD (thiamine tetrahydrofurfuryl disulfide, often labeled “allithiamine”) and benfotiamine, get around this limit because they cross cell membranes by simple diffusion, then get converted back to thiamine inside the cell.

Where TTFD comes from

TTFD was developed in Japan in the 1960s after researchers noticed that garlic and rice-bran extracts produced a longer-lasting thiamine effect than ordinary thiamine alone. The lipid-soluble disulfide form passes through cell membranes, including the blood–brain barrier, and is broken down inside cells to release free thiamine. In tissue and blood measurements, TTFD raises intracellular thiamine to levels that ordinary oral thiamine cannot reach (Lonsdale 2006; PMID 16550223).

Neurological uses

TTFD has been studied in conditions where the brain has trouble using thiamine: pyruvate dehydrogenase deficiency, subacute necrotizing encephalomyelopathy (Leigh syndrome), and a range of fatigue syndromes. Reports are mostly case series and small open-label studies, with randomized evidence still limited. Wider clinical use in dysautonomia, POTS, and migraine has run ahead of the formal trial data, so claims should be treated cautiously.

Benfotiamine: the diabetic-neuropathy cousin

Benfotiamine (S-benzoylthiamine O-monophosphate) is another fat-soluble thiamine derivative. It is best studied for painful diabetic neuropathy. The BENDIP randomized trial (Stracke 2008, Experimental and Clinical Endocrinology & Diabetes; PMID 18473286) tested benfotiamine 300–600 mg/day over 6 weeks and reported modest symptom improvement on the TSS pain score. Unlike TTFD, benfotiamine does not enter the brain efficiently — it acts mainly in peripheral nerves and tissues (Volvert 2008, BMC Pharmacology; PMID 18549472).

Dosing and caveats

TTFD is usually taken at 50–200 mg/day with a meal that contains some fat. Some users report a short-lived rough patch — worse fatigue or anxiety for 1–3 weeks — in the first weeks of use, which clinicians who use TTFD describe as a “paradoxical reaction.” Starting at 10–25 mg and slowly working up usually avoids this. TTFD is well tolerated long term but has a noticeable sulfur odor that some people dislike.